This 2022 position statement by the North American Menopause Society (NAMS) updates the 2017 guidance on hormone therapy (HT) for menopausal individuals. HT remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause and is shown to prevent bone loss and fractures. The benefits and risks of
